NEW YORK, September 29, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following equities: Celldex Therapeutics, Inc. (NASDAQ: CLDX), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Advaxis, Inc. (NASDAQ: ADXS), BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Cytori Therapeutics Inc. (NASDAQ: CYTX). On Monday, September 28, 2015, NASDAQ ended at 4,543.97 down 3.04%, Dow Jones declined 1.92%, to finish the day at 16,001.89, and the S&P closed at 1,881.77, down 2.57%. Register for your complimentary reports at the links given below.
--
Celldex Therapeutics Inc.
--
Celldex Therapeutics Inc.'s stock edged lower by 10.18% to close Monday's session at USD 10.94. The company's shares oscillated between USD 10.73 and USD 12.16 marking a new 52-week low during the session. The stock recorded a trading volume of 2.95 million shares, which was above its 50-day daily average volume of 1.80 million shares and above its 52-week average volume of 2.15 million shares. Over the last three days, Celldex Therapeutics Inc's shares have declined by 17.74% and in the past one week it has moved down 23.12%. Furthermore, over the last three months, the stock has lost 53.78% and in the past six months, the shares have shed 60.70%. The stock is trading at a price to book ratio of 3.12 while the historical PB ratio is close to 7.72. Sign up and read the free notes on CLDX at: http://www.aciassociation.com/CLDX.pdf
--
Alexion Pharmaceuticals Inc.
--
The stock of Alexion Pharmaceuticals Inc. lost 2.45% to close Monday's session at USD 145.60. The shares of the company moved in the range of USD 142.02 and USD 149.98 marking a new 52-week low during the session. A trading volume of 2.79 million shares was recorded, which was greater than its 150-day daily average volume of 1.82 million shares and above its 52-week average volume of 1.58 million shares. Over the last five days, Alexion Pharmaceuticals Inc.'s shares have declined by 9.29% and in the past one month, it has lost 16.10%. Additionally, over the last three months, the stock has declined 18.09% and in the past six months, the shares have registered a loss of 19.23%. Further, the company is trading at a price to earnings ratio of 49.86 and the stock is at a price to book ratio of 3.85. This compares to a historical PE ratio of 56.79 and a historical PB ratio close to 11.15. Register for free on ACI Association and access the latest research on ALXN at: http://www.aciassociation.com/ALXN.pdf
--
Advaxis Inc.
--
Advaxis Inc.'s stock decreased by 11.60% to close Monday's session at USD 12.19. The company's shares fluctuated in the range of USD 11.36 and USD 13.78. A total of 2.77 million shares exchanged hands, which surpassed its 50-day daily average volume of 1.24 million shares and was above its 52-week average volume of 1.25 million shares. Over the last three days Advaxis Inc.'s shares have declined by 18.30% and in the past one week it has moved down 23.76%. Furthermore, over the last three months, the stock has lost 29.37% and in the past six months, the shares have shed 9.30%. The complete research on ADXS is available for free at: http://www.aciassociation.com/ADXS.pdf
--
BioDelivery Sciences International Inc.
--
BioDelivery Sciences International Inc.'s stock slipped by 12.05% to close Monday's session at USD 5.33. The company's shares oscillated between USD 5.19 and USD 6.19 marking a new 52-week low during the session. The stock recorded a trading volume of 2.36 million shares, which was above its 50-day daily average volume of 1.40 million shares and above its 52-week average volume of 1.09 million shares. Over the last five days, BioDelivery Sciences International Inc.'s shares have declined by 28.74% and in the past one month, it has lost 17.30%. In addition, over the last three months, the stock has lost 26.58% and year to date, the shares have shed 55.66%. The stock is trading at a price to book ratio of 8.00 while the historical PB ratio is close to 11.40. Free in-depth research on BDSI is available at: http://www.aciassociation.com/BDSI.pdf
--
Cytori Therapeutics Inc.
--
Cytori Therapeutics Inc.'s stock advanced 2.33% to close Monday's session at USD 0.37. The share price vacillated between USD 0.32 and USD 0.37. The stock recorded a trading volume of 2.09 million shares, which was above its 50-day daily average volume of 1.88 million shares and below its 52-week average volume of 2.69 million shares. Over the last three days Cytori Therapeutics Inc.'s shares have declined by 1.05% and in the past one week it has moved down 6.57%. Moreover, in the last six months, the stock has lost 69.30% and year to date, the shares have shed 24.62%. The stock is trading at a price to book ratio of 24.61 and price to sales ratio of 5.72. The complimentary notes on CYTX can be downloaded in PDF format at: http://www.aciassociation.com/CYTX.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE www.aciassociation.com